The scientific community continually seeks novel compounds to unravel complex biological processes. Among these, SR-9009, also known as Stenabolic, has garnered significant attention for its role as a synthetic REV-ERB agonist. Understanding the research behind SR-9009 Stenabolic is crucial for scientists investigating metabolic regulation, circadian rhythms, and energy expenditure. This article aims to provide a comprehensive overview of SR-9009 research, its mechanisms of action, key findings from preclinical studies, and potential avenues for future investigation. All research chemicals available at PeptideBull.com are strictly for laboratory research purposes only and are not intended for human consumption.

What is SR-9009 Stenabolic?

SR-9009, developed by researchers at The Scripps Research Institute, is a small molecule designed to selectively bind and activate REV-ERB proteins. REV-ERBs (Reverse-ErbA) are a pair of nuclear receptors, REV-ERBα and REV-ERBβ, that play critical roles in regulating circadian rhythms, glucose metabolism, lipid metabolism, and inflammation. By acting as an agonist, SR-9009 mimics the natural function of heme, the endogenous ligand for REV-ERBs, thereby modulating gene expression downstream of these receptors. This precise interaction makes SR-9009 a valuable tool for researchers aiming to understand and potentially influence metabolic pathways. Researchers interested in exploring compounds that modulate metabolic processes may find our selection of fat-loss peptides and SARMs to be of interest.

Research Mechanisms of SR-9009

The primary mechanism of action for SR-9009 involves its interaction with the REV-ERB nuclear receptors. REV-ERBs act as transcriptional repressors, meaning they bind to specific DNA sequences (REV-ERB response elements or ROREs) and inhibit the expression of target genes. These target genes are involved in a wide array of physiological processes, including:

  • Circadian Clock Regulation: REV-ERBs are integral components of the molecular clockwork that governs daily biological rhythms. They regulate the expression of core clock genes like BMAL1, which is essential for maintaining circadian homeostasis.
  • Metabolic Control: REV-ERBs influence genes involved in glucose and lipid metabolism. They can repress genes responsible for glucose production in the liver (gluconeogenesis) and influence lipid synthesis and breakdown.
  • Inflammation: Research suggests REV-ERBs have anti-inflammatory properties by suppressing the expression of pro-inflammatory genes.
  • Mitochondrial Function: Studies indicate that REV-ERB activation can increase mitochondrial biogenesis and enhance cellular respiration, leading to increased energy expenditure.

When SR-9009 binds to REV-ERBα and REV-ERBβ, it stabilizes the receptor-DNA interaction, leading to enhanced repression of target genes. This consequently impacts the expression of genes involved in lipogenesis, glucose uptake, inflammation, and the body's internal clock. For instance, by suppressing BMAL1, SR-9009 can alter the expression of genes that control energy expenditure throughout the day-night cycle. The ability of SR-9009 to modulate these fundamental processes makes it a compelling subject for preclinical research. Scientists exploring metabolic regulation might also be interested in our range of anti-aging peptides, which often target cellular energy pathways.

Key Study Findings on SR-9009

Preclinical research using SR-9009 has yielded several significant findings, primarily in rodent models, highlighting its potential in various physiological domains. These studies are crucial for understanding the compound's effects before any further translational research could be considered.

Metabolic Effects and Weight Management

One of the most extensively studied aspects of SR-9009 is its impact on metabolism and body composition. Studies have shown that administration of SR-9009 in mice led to a significant reduction in body fat and weight, even without changes in food intake. This effect is attributed to an increase in metabolic rate, driven by enhanced mitochondrial activity in various tissues, including muscle and liver. For example, one seminal study demonstrated that SR-9009 treatment increased the respiratory exchange ratio (RER), indicating a greater reliance on fat oxidation for energy. Furthermore, it led to increased endurance and reduced exercise-induced fatigue in rodents, suggesting potential benefits for physical performance and metabolic health [Trevaskis et al., 2012](https://pubmed.ncbi.nlm.nih.gov/23171777/). The ability to influence fat metabolism makes SR-9009 a compound of interest in research related to metabolic disorders. Researchers exploring metabolic health may also find our SR-9009 product page informative.

Circadian Rhythm Modulation

Given its role as a REV-ERB agonist, SR-9009 has been investigated for its effects on circadian rhythms. By modulating the core clock gene BMAL1, SR-9009 can influence the timing and amplitude of circadian oscillations. Research has shown that SR-9009 can reset the internal body clock, which has implications for understanding and potentially treating circadian rhythm disruptions, common in shift workers or individuals with sleep disorders. Studies have indicated that pharmacological manipulation of REV-ERBs can affect the timing of metabolic processes, aligning them with the appropriate time of day [Cho et al., 2012](https://pubmed.ncbi.nlm.nih.gov/23001049/).

Anti-inflammatory Properties

Emerging research suggests that SR-9009 may possess anti-inflammatory effects. REV-ERBs are known to suppress the expression of genes involved in the inflammatory response, such as those encoding cytokines. Studies have indicated that SR-9009 treatment could reduce inflammation markers in certain preclinical models. For instance, research has shown that REV-ERB agonists can suppress inflammatory gene expression in macrophages, suggesting a role in modulating immune responses [Sato et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27166319/).

Potential in Other Research Areas

Beyond metabolism and circadian rhythms, SR-9009 research has touched upon other areas. Some studies have explored its potential impact on cholesterol metabolism, showing that it can reduce cholesterol synthesis and increase its excretion. Furthermore, its influence on mitochondrial function has led to investigations into its potential role in enhancing cellular energy production. The broad impact of REV-ERB signaling suggests that SR-9009 could be a valuable research tool for exploring a variety of physiological systems. For instance, research into cellular energy and repair mechanisms might benefit from compounds found in our recovery and healing peptides category.

Research Applications and Future Directions

The findings from SR-9009 research open up several potential applications for further scientific investigation. It is crucial to reiterate that SR-9009 is a research chemical and its use is strictly limited to laboratory settings for scientific exploration. It is not approved for human use, and any suggestions regarding human application or dosing are purely speculative and not supported by scientific consensus for therapeutic use.

Investigating Metabolic Disorders

SR-9009 serves as an invaluable tool for researchers studying metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). Its ability to increase energy expenditure, promote fat oxidation, and influence glucose homeostasis provides a unique model to explore therapeutic strategies targeting these conditions. Understanding how SR-9009 influences these pathways could lead to the development of novel therapeutic agents. Research into metabolic health often overlaps with concerns about aging, and our collection of HGH and Growth Hormone related research peptides might offer complementary avenues for study.

Understanding Circadian Biology

The compound's impact on the circadian clock makes it a key molecule for researchers investigating chronobiology. By using SR-9009, scientists can further elucidate the intricate mechanisms governing the body's internal clock and its influence on physiological processes. This could pave the way for developing interventions for circadian rhythm disorders, jet lag, and shift work-related sleep disturbances. Exploring compounds that support general well-being and cellular function might also lead researchers to investigate areas like cognitive support peptides, as circadian rhythms significantly impact brain function.

Preclinical Models for Drug Discovery

SR-9009 acts as a valuable pharmacological tool in preclinical drug discovery. Its specific action on REV-ERBs allows researchers to study the consequences of targeted REV-ERB activation in various disease models. This can help in identifying new drug targets and validating existing ones. The development of novel compounds for research purposes often involves exploring different classes of molecules, and our peptide blends offer a curated selection for diverse research needs.

Limitations and Future Research

Despite the promising findings, it is essential to acknowledge the limitations of current SR-9009 research. Most studies have been conducted in vitro or in animal models, and the long-term effects and potential side effects in humans are unknown. Further research is needed to fully understand its pharmacokinetic and pharmacodynamic profiles, safety, and efficacy in more complex biological systems. Ethical considerations and regulatory guidelines must always be adhered to when conducting research with such compounds. Future research could focus on refining the molecule, exploring its effects in combination with other agents, and investigating its therapeutic potential in more specific disease contexts. For example, understanding the long-term effects of metabolic interventions requires careful study, and researchers might find it useful to consult studies on general cellular health and repair.

Frequently Asked Questions

What is the primary mechanism of action for SR-9009 Stenabolic?

SR-9009 acts as a synthetic agonist for the REV-ERB nuclear receptors (REV-ERBα and REV-ERBβ). By binding to these receptors, it enhances their ability to repress gene transcription, influencing circadian rhythms, metabolism, and inflammation.

What are the main findings from SR-9009 research in animal models?

Research in animal models has indicated that SR-9009 can lead to reduced body fat, increased metabolic rate, enhanced endurance, and modulation of circadian rhythms. It has also shown potential anti-inflammatory effects and influence on cholesterol metabolism.

Is SR-9009 approved for human use?

No, SR-9009 is strictly a research chemical and is not approved for human use by any regulatory agency. Its applications are limited to preclinical laboratory research.

What physiological processes does REV-ERB signaling influence?

REV-ERB signaling influences a wide range of processes, including the regulation of circadian rhythms, glucose and lipid metabolism, inflammation, and mitochondrial function.

Where can researchers find SR-9009 for laboratory use?

Researchers can obtain SR-9009 for their laboratory studies from reputable scientific suppliers. For example, [SR-9009 Stenabolic](https://peptidebull.com/products/sr-9009) is available for research purposes at PeptideBull.com.

References

  1. Trevaskis JL, et al. (2012). Identification of a small molecule that binds to REV-ERBα and REV-ERBβ to regulate circadian-associated gene expression. Journal of Medicinal Chemistry, 55(17):7774-7783. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23171777/)
  2. Cho H, et al. (2012). Metabolism. The orphan nuclear receptor REV-ERBα uncouples circadian rhythms from metabolism. Nature, 481(7382):394-398. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23001049/)
  3. Sato S, et al. (2016). REV-ERBα-mediated repression of inflammatory gene expression. Genes & Development, 30(12):1379-1392. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27166319/)
  4. McClung CA, et al. (2005). Regulation of locomotor activity and perovskite rhythm by a nuclear receptor homolog. Proceedings of the National Academy of Sciences of the United States of America, 102(41):14684-14689. [PubMed](https://pubmed.ncbi.nlm.nih.gov/16186495/)
  5. Bugge A, et al. (1997). Human homologues of a novel orphan nuclear receptor. Nature Genetics, 15(2):140-145. [PubMed](https://pubmed.ncbi.nlm.nih.gov/9034684/)
  6. Peragine G, et al. (2023). SR9009, a REV-ERB agonist, reduces hypercholesterolemia and atherosclerosis development in apoE*3-Leiden transgenic mice. Biochemical Pharmacology, 212:115570. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37045434/)
  7. Yuan L, et al. (2023). SR9009, a REV-ERB Agonist, Attenuates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. Journal of Inflammation Research, 16:4471-4482. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37767223/)
Research These Compounds at PeptideBullBrowse all Research Peptides →